SCHEMBL4049320

SCHEMBL4049320

N#Cc1c(O)c(-c2ccsc2)n[nH]c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
ADORA2A P29274 3/20 0.43
ADORA1 P30542 3/20 0.43
FLT4 P35916 1/20 0.41
MAPK8 P45983 1/20 0.41
MAPK9 P45984 1/20 0.41
CSNK2A1 P68400 1/20 0.41
DYRK1A Q13627 1/20 0.41
AURKB Q96GD4 1/20 0.41
PRKD2 Q9BZL6 1/20 0.41
ACMSD Q8TDX5 1/20 0.40
LRRK2 Q5S007 1/20 0.37
PTGES O14684 2/20 0.37
GRIN2D O15399 1/20 0.36
GRIN3B O60391 1/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2A Q12879 1/20 0.36
GRIN2B Q13224 1/20 0.36
GRIN2C Q14957 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4052572 0.75 PRNP (0.50) MEN1KMT2AADORA2AADORA1ACMSD
SCHEMBL31014291 0.70 ATM (0.64) ADORA2A
SCHEMBL9251834 0.70 ATM (0.64) ADORA2A
SCHEMBL4137561 0.68 MAPK8 (0.38) ADORA2AADORA1FLT4MAPK8MAPK9
SCHEMBL4142975 0.68 ADORA1 (0.40) MEN1KMT2AADORA2AADORA1FLT4
SCHEMBL4057666 0.68 CDK4 (0.41) ADORA2AADORA1ACMSDCDK4CCND1
SCHEMBL13905617 0.67 MERTK (0.41) ADORA2AADORA1FLT4MAPK8MAPK9
SCHEMBL4052051 0.66 ADORA1 (0.38) ADORA2AADORA1FLT4MAPK8MAPK9
SCHEMBL4123867 0.66 MAPK8 (0.37) MEN1KMT2AADORA2AADORA1FLT4
SCHEMBL4126223 0.66 GRM2 (0.40) ADORA2AADORA1FLT4MAPK8MAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009032179-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI IDENIX PHARMACEUTICALS, INC. (US) 2009-03-12 WO disclosed
US-20090060867-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI IDENIX PHARMACEUTICALS, INC. (US) 2009-03-05 US disclosed
US-20090060867-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI IDENIX PHARMACEUTICALS, INC. (US) 2009-03-05 US disclosed
US-20090060867-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI IDENIX PHARMACEUTICALS, INC. (US) 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090060867-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI POLR2E, POLR2H, POLI MEN1 4809/4885KMT2A 3032/4885ADORA2A 2513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.